Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Humacyte, Inc. (HUMA) declined 7.88% to close at $0.36, significantly underperforming the broader market. The stock has lost 30.55% over the past month, lagging the Medical sector's gains. Analysts expect the company to report a loss of $0.09 per share in the upcoming earnings release, though this represents a 35.71% year-over-year improvement. The company holds a Zacks Rank of #3 (Hold), with the Medical - Biomedical and Genetics industry ranked in the bottom 35% of all industries.